Universal Health Services, Inc. (UHS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented optimistic guidance with a 6% increase in EPS, promising hospital openings, and growth in behavioral health and acute care segments. The Q&A section reinforced confidence in achieving growth targets and margin expansion. Despite uncertainties in Medicaid and staffing requirements, the company's strategic investments and AI-driven efficiencies suggest a positive outlook. The positive sentiment from management and analysts, combined with strategic growth plans, indicates a likely positive stock price reaction over the next two weeks.
Key Financial Performance
Q4 2025 Revenue Growth 9% year-over-year increase, driven by strong expense management in acute care, sequential volume improvements in behavioral health, and solid pricing across both segments.
Q4 2025 Adjusted EBITDA net of NCI 10% year-over-year increase, attributed to effective cost management and operational improvements.
Q4 2025 Adjusted EPS 20% year-over-year increase, reflecting strong financial performance and share repurchase activity.
Full Year 2025 Revenue Growth 10% year-over-year increase, supported by new inpatient capacity and outpatient service expansions.
Full Year 2025 Adjusted EBITDA net of NCI 15% year-over-year increase, due to reduced contract labor costs and improved supply chain management.
Full Year 2025 Adjusted EPS 31% year-over-year increase, driven by operational efficiencies and share repurchase activity.
Acute Care Same-Facility Net Revenues (Q4 2025) 6.9% year-over-year increase, with a 5.4% increase in revenue per adjusted admission, excluding the Las Vegas market.
Behavioral Health Same-Facility Net Revenues (Q4 2025) 7.2% year-over-year increase, supported by a 5.6% increase in revenue per adjusted patient day and a 1.5% increase in adjusted patient days.
Behavioral Health Segment EBITDA (Q4 2025) 6.9% year-over-year growth, attributed to headcount growth and investments in staffing capacity.
Behavioral Health Segment EBITDA (Full Year 2025) 7.8% year-over-year growth, reflecting stable margins and operational improvements.
Cash Generated from Operating Activities (2025) $1.9 billion, compared to $2.1 billion in 2024, impacted by increased receivables and timing of Medicaid supplemental payments.
Capital Expenditures (2025) $1 billion, with 35% allocated to new hospital projects and major expansions.
Share Repurchase Activity (2025) 4.65 million shares acquired at a total cost of $899 million, including 1.46 million shares in Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New inpatient capacity: Opened 2 new acute care hospitals in the past 2 years and laid groundwork for 3 inpatient expansions totaling 178 licensed beds in Florida, California, and Nevada. A new 156-bed hospital in Palm Beach Gardens, Florida, will open in Q2 2026.
Outpatient behavioral locations: Operates 119 outpatient behavioral locations, including 10 new freestanding centers opened in 2025 under the 1,000 branches Wellness brand. Plans to open at least 10 more in 2026.
Behavioral de novo projects: Two projects totaling 264 beds planned for 2026, including a joint venture with Jefferson Health System in Pennsylvania.
Revenue growth: Revenue grew 9% in Q4 2025 and 10% for the full year compared to 2024.
Adjusted EBITDA and EPS: Adjusted EBITDA net of NCI increased 10% in Q4 2025 and 15% for the full year. Adjusted EPS increased 20% in Q4 and 31% for the full year.
Expense management: Acute care margins improved due to reduced contract labor costs and strong supply chain management. Labor productivity improved with a 2% reduction in same-facility acute care length of stay.
Technology adoption: Deployed AI to improve post-discharge care, reduce readmissions, and enhance revenue cycle operations. Plans to roll out new patient safety technologies in behavioral health and expand AI use in acute care in 2026.
Outpatient behavioral strategy: Focused on accelerating outpatient behavioral growth rate, diversifying payer mix, and expanding service offerings to maintain leadership.
Stock repurchase: Repurchased 4.65 million shares in 2025 at a total cost of $899 million, with $1.425 billion remaining in repurchase authorization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Acute Care Volumes: Acute care volumes were impacted by softness in the Las Vegas market due to transitory factors, including lower respiratory case levels year-over-year.
Health Insurance Exchanges: A reduction in health insurance exchange volumes is expected to have an adverse pretax earnings impact of approximately $75 million in 2026. Exchange volumes are projected to decline by 25%-30%, with most shifting to self-pay or uninsured categories.
California Psychiatric Staffing Regulations: New California inpatient psychiatric hospital staffing regulations, effective June 1, 2026, are expected to increase labor costs and cause short-term census disruption, with an estimated $35 million negative pretax earnings impact in 2026.
Medicaid Supplemental Payments: The 2026 outlook assumes a net benefit from Medicaid supplemental payments of $1.36 billion, but this is contingent on program approvals, introducing uncertainty.
Labor Constraints in Behavioral Health: Staffing constraints in certain markets have impacted volume growth in the Behavioral Health segment, requiring investments in headcount.
Winter Storms Impact: Winter storms are expected to negatively impact first-quarter 2026 volumes in the Behavioral Health segment and Washington, D.C. Acute Care operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Expected to range between $18.4 billion and $18.8 billion, representing growth of 6% to 8% for 2026.
Adjusted EBITDA: Expected to range between $2.64 billion and $2.79 billion, representing growth of 2% to 8% for 2026.
Adjusted Net Income: Expected to range between $22.64 and $24.52 per diluted share, representing growth of 4% to 13% for 2026.
Same-Facility Volume Growth: Projected to be in the range of 2% to 3% for both segments for the full year 2026, with potential softness in Q1 due to winter storms.
Capital Expenditures: Expected to range between $950 million and $1.1 billion in 2026, reflecting spending on large inpatient projects coming online in the first half of the year.
Health Insurance Exchange Impact: Anticipated adverse pretax earnings impact of approximately $75 million due to a 25%-30% decline in exchange volumes, with most shifting to self-pay or uninsured.
California Staffing Regulations: Expected negative pretax earnings impact of approximately $35 million in 2026 due to new staffing regulations, with ongoing costs of $30 million annually beyond 2026.
Medicaid Supplemental Payments: Net benefit expected to increase by approximately $23 million in 2026, totaling $1.36 billion.
Cedar Hill Improvements: Expected $50 million favorability related to operational improvements, offset by start-up costs for the new hospital in Palm Beach Gardens.
Behavioral Segment M&A: Modest contributions expected from acquisitions completed in 2025, primarily in the U.K.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Activity: During 2025, the company acquired 4.65 million of its shares at a total cost of $899 million, including 1.46 million shares purchased during the fourth quarter of 2025. At the end of 2025, the company had $1.425 billion of repurchase authorization available pursuant to its stock buyback program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the expected volume growth for 2026 across both segments, and what are the pricing assumptions?
A:The guidance for 2026 includes a 2% to 3% volume growth across both segments. On the acute side, pricing is expected to increase by 3% to 4%, in line with the 10-year average. On the behavioral side, pricing is expected to grow by 2% to 3%, which is slightly lower than recent years but consistent with historical rates.
Q:What is the financial impact of AI applications on operating performance, and when might it be realized?
A:The company is in the early stages of AI adoption, focusing on administrative tasks like revenue cycle management and post-discharge activities. AI has driven efficiencies, reduced headcount, and improved outcomes, but it is difficult to precisely quantify the financial impact or timeline for significant revenue or margin improvements.
Q:What are the assumptions for surgical versus medical volume growth in 2026, and how is the Nevada market expected to perform?
A:Surgical volumes are expected to grow slightly slower than overall volumes but remain positive. The Nevada market, which grew in line with the acute division in 2025, is expected to experience an uptick in 2026 due to stable employment trends and bullish prospects in the gaming industry.
Q:What is the visibility on exchange volumes and potential bad debt?
A:The company assumes a 25% to 30% decline in exchange volumes based on public projections. Early data suggests a decline, but the full impact will become clearer in the coming months. There is a risk of bad debt as insurance companies may not reimburse charges if premiums are unpaid, but this has been factored into the company's assumptions.
Q:What is the $35 million headwind from California behavioral staffing requirements, and why does it not annualize into a larger run rate?
A:The $35 million headwind in 2026 is due to upfront investments in hiring more licensed professionals, particularly RNs, and potential short-term volume disruptions. The ongoing annual impact is expected to be $30 million as startup costs and infrastructure investments will not recur in 2027 and beyond.
Q:What is the demand for outpatient behavioral services, and how does it fit into the long-term business mix?
A:Outpatient services currently represent about 10% of the Behavioral segment revenue and are expected to grow. The company operates nearly 120 outpatient locations offering step-down and step-in services. Demand for these services is expected to increase, and the company plans to open at least 10 new outpatient locations in 2026.
Q:What are the potential impacts of California's new staffing requirements on wages and reimbursement?
A:The company has accounted for potential wage inflation and recruitment costs due to staffing changes. While efforts will be made to negotiate higher reimbursement rates with payers, no such increases have been included in the current forecast.
Q:Can the behavioral business achieve organic margin expansion with 2% to 3% volume and pricing growth?
A:Yes, the 4% to 6% revenue growth from 2% to 3% volume and pricing increases is expected to exceed operating cost growth, allowing for margin expansion. Additionally, the growth in outpatient services, which have better margins, will further support margin expansion.
Q:What are the opportunities to reduce acute length of stay (LOS), and what are the challenges?
A:On an acuity-adjusted basis, LOS is below pre-pandemic levels due to internal initiatives and technology. However, the lack of subacute capacity in many markets remains a significant obstacle. Improvements in subacute capacity and internal efficiencies are expected to reduce LOS further.
Q:What is the status of Medicaid supplemental programs in Florida and California?
A:The Florida program is expected to be approved, with a potential benefit of $45 million to $50 million. The California program faces more hurdles and may require significant modifications for approval. The company has not quantified the potential benefit from California.
Q:What is the company's leverage strategy, and are there plans for significant M&A?
A:The company aims to maintain leverage in the 2x to 3x range to retain flexibility for potential M&A opportunities. While share repurchases are ongoing, there are no plans to significantly increase leverage unless compelling M&A opportunities arise.
Q:What are the real examples of AI-driven efficiencies in revenue cycle management?
A:AI has been used for post-discharge calls and revenue cycle management, leading to reduced headcount and improved outcomes. The company is also exploring AI applications in patient safety and intake processes, but exact financial benefits are difficult to quantify at this stage.
Q:What is the confidence level in achieving 2% to 3% behavioral volume growth in 2026?
A:The company is confident in achieving 2% to 3% volume growth due to sequential improvements in 2025 and investments in staffing to address volume growth obstacles.
Q:What are the key capital investment areas for 2026?
A:Key investments include new hospital projects, outpatient facility expansion, and enhancements to emergency room and surgical capacity. These investments align with the company's focus on both inpatient and outpatient growth.
Q:What is the outlook for Medicaid work requirements and funding cuts?
A:The impact of Medicaid work requirements starting in 2027 is uncertain, as specific requirements and their effects on utilization are not yet clear. The company will monitor developments and adjust accordingly.
Q:What is the cash flow outlook for 2026?
A:Cash flow from operations is expected to align with historical levels, approximately 75% to 80% of operating income less NCI. Timing issues with receivables are not expected to materially impact cash flow.
Q:What are the supply cost trends for 2026?
A:Supply costs were well-controlled in 2025 and are not expected to face significant pressure in 2026. Opportunities for cost efficiency will focus on clinician preferences for high-cost items.
Q:What is the long-term outlook for behavioral pricing and Medicaid volume strategy post-2028?
A:While DPP reimbursement is expected to decline starting in 2028, the company plans to offset this by growing its outpatient business, which has better margins and a higher commercial payer mix. The 2% to 3% volume growth target is expected to remain achievable.
Q:How does the 3.5% to 4% growth in behavioral FTEs in 2025 support 2026 volume growth?
A:The growth in FTEs addressed staffing vacancies that were obstacles to volume growth. This investment positions the company to achieve its 2% to 3% volume growth target in 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing precise financial impacts or timelines for AI applications, citing difficulty in quantification. Similarly, they did not provide specific estimates for the impact of Medicaid work requirements starting in 2027, citing uncertainty in state-level implementation and utilization patterns. Additionally, while acknowledging the potential for reimbursement increases in California due to new staffing requirements, no concrete expectations were set.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI care
AI department
AI feature
AI solution
Agentic AI
California Nevada
Conference Lehrich
Conference today
Difficulty outcome
Filton detail
Florida California
Florida segment
Gardens Florida
Health System
Investor Relations
Jefferson
Lehrich Vice
President Investor
Services Conference
addition
agenda
bed
branch
experience efficiency
improvement technology
investment
location
measure
net NCI
novo
opportunity
quality experience
risk factor
technology health
volume improvement
UHS Transcript
Universal Health Services, Inc. (UHS) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call presented optimistic guidance with a 6% increase in EPS, promising hospital openings, and growth in behavioral health and acute care segments. The Q&A section reinforced confidence in achieving growth targets and margin expansion. Despite uncertainties in Medicaid and staffing requirements, the company's strategic investments and AI-driven efficiencies suggest a positive outlook. The positive sentiment from management and analysts, combined with strategic growth plans, indicates a likely positive stock price reaction over the next two weeks.
Universal Health Services, Inc. (UHS) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Neutral11-19
Universal Health Services, Inc. (UHS) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call presents a mixed but overall positive outlook. The increase in 2025 EPS guidance and positive EBITDA from new facilities are strong positives. Despite some challenges, such as startup losses and cannibalization, the optimistic guidance and strategic expansions in behavioral health are promising. The Q&A reveals some concerns, but the overall sentiment leans positive, especially with increased guidance and strategic growth plans. No strong negative factors were highlighted, and the company's proactive approach to challenges suggests a likely positive stock price movement.
Universal Health Services, Inc. (UHS) Presents At Baird Global Healthcare Conference 2025 Transcript
Neutral9-10
UHS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
